← Back to Search

Marijuana and Alcohol Effects on Driving Impairment (Alc-NHTSA Trial)

Hartford, CT
Phase < 1
Waitlist Available
Led By Godfrey Pearlson, M.D
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Must not have
history of head trauma with loss of consciousness > 30 minutes or concussion lasting 30 days.
any medical/neurological condition that could compromise neurocognitive performance (i.e. epilepsy, multiple sclerosis, fetal alcohol syndrome)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours

Summary

This trial looks at the effects of smoking marijuana and drinking alcohol on driving.

See full description
Who is the study for?
This trial is for adults who regularly drink alcohol and smoke marijuana, with at least 2 years of cannabis use and driving experience. They must not be novice users, should have used cannabis at least five times in their life without withdrawal symptoms, and hold a valid driver's license.Check my eligibility
What is being tested?
The study tests the effects of different levels of marijuana (high to low) and alcohol (0.08 BAC to placebo) on simulated driving performance. It aims to understand how these substances combined can impair driving abilities.See study design
What are the potential side effects?
Since this trial involves the consumption of marijuana and alcohol, side effects may include typical reactions such as dizziness, altered perception, coordination issues, delayed reaction times, euphoria or anxiety.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a head injury with unconsciousness for over 30 minutes or a concussion that lasted 30 days.
 show original
Select...
I do not have conditions like epilepsy that affect my brain function.
 show original
Select...
I do not have any serious illnesses like cancer, seizures, or brain diseases.
 show original
Select...
I have been diagnosed with a mental health condition.
 show original
Select...
A close family member has a psychotic disorder.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and post drug administration at: 10 min; 1.5 hours 2.5 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Ethanol
Marijuana and alcohol induced performance changes on Cogstate 1-back/2-back task.
Ethanol
+13 more
Secondary study objectives
Change in concentration of THC/metabolites in blood samples.
Change in concentration of THC/metabolites in oral fluid tested using Quantisal Oral Fluid Collection devices.
Change in performance on simulated driving Car Following Task.
+2 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Placebo Drug + 0.08 BAC AlcExperimental Treatment2 Interventions
Participants will receive placebo drug with no THC along with alcohol leading to a BAC of 0.08.
Group II: Placebo Drug + 0.05 BAC AlcExperimental Treatment2 Interventions
Participants will receive placebo drug with no THC along with alcohol leading to a BAC of 0.05.
Group III: Low Dose THC + 0.05 BAC AlcExperimental Treatment2 Interventions
Participants will receive low dose of THC along with alcohol leading to a BAC of 0.05.
Group IV: High Dose THC + 0.05 BAC AlcExperimental Treatment2 Interventions
Participants will receive high dose of THC along with alcohol leading to a BAC of 0.05.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Closest Location:Hartford Hospital· Hartford, CT

Who is running the clinical trial?

National Highway Traffic Safety AdministrationUNKNOWN
1 Previous Clinical Trials
26 Total Patients Enrolled
Yale UniversityLead Sponsor
1,957 Previous Clinical Trials
3,045,489 Total Patients Enrolled
1 Trials studying Cannabis Intoxication
9 Patients Enrolled for Cannabis Intoxication
National Highway Traffic Safety Administration (NHTSA)FED
7 Previous Clinical Trials
929 Total Patients Enrolled
Hartford HospitalOTHER
139 Previous Clinical Trials
19,681 Total Patients Enrolled
1 Trials studying Cannabis Intoxication
9 Patients Enrolled for Cannabis Intoxication
National Institute on Drug Abuse (NIDA)NIH
2,654 Previous Clinical Trials
3,409,241 Total Patients Enrolled
2 Trials studying Cannabis Intoxication
180 Patients Enrolled for Cannabis Intoxication
Godfrey Pearlson, M.DPrincipal Investigator - Founding Director, Olin Neuropsychiatry Center; Yale University
Yale University
3 Previous Clinical Trials
62 Total Patients Enrolled

Media Library

Laboratory Evaluations Clinical Trial Eligibility Overview. Trial Name: NCT04856566 — Phase < 1
Cannabis Intoxication Research Study Groups: Low Dose THC + 0.05 BAC Alc, High Dose THC + 0.05 BAC Alc, Placebo Drug + 0.05 BAC Alc, Placebo Drug + 0.08 BAC Alc
Cannabis Intoxication Clinical Trial 2023: Laboratory Evaluations Highlights & Side Effects. Trial Name: NCT04856566 — Phase < 1
Laboratory Evaluations 2023 Treatment Timeline for Medical Study. Trial Name: NCT04856566 — Phase < 1
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top